clinical trials and stem cell treatments

EuroStemCell toolkit

A growing set of downloadable, mix-and-match stem cell resources and activities suitable for a variety of educational settings. All components have been extensively tested, and come with full instructions.

Available in several European languages.

New website takes a closer look at stem cells

The International Society for Stem Cell Research (ISSCR) has launched a new website to help patients and their families make informed decisions about stem cell treatments, clinics and their health.

Stem Cells Australia's Megan Munsie, chairperson of the ISSCR task force responsible for the website expansion, describes the revamped site as “a direct channel from researchers to the public.”

Scientists taking a stand

When scientists speak up for science, it can be a powerful thing indeed. We regularly observe this - in the direct interactions between scientists and school pupils or patient groups, for example, that are part of our public engagement and outreach work - but it also applies on the wider political stage.

Making insulin producing beta cells from stem cells – how close are we?

The unseen world: Insulin-producing cells made from human embryonic stem cellsThe unseen world: Insulin-producing cells made from human embryonic stem cells

Two recent studies have revealed for the first time how to to generate insulin producing cells, that resemble normal beta cells, in the lab from human pluripotent stem cells. This provides a step forward for a potential cell therapy treatment for diabetes. But how alike are these cells to the beta cells found in our bodies? How close are we to testing these cells in diabetics? And what other questions still remain? In this commentary, Henrik Semb tackles these questions providing perspective in this complex and challenging field.

New study raises doubts over the benefits of heart stem cell therapy


Numerous clinical trials have attempted to test the benefits of using a patient’s own stem cells (taken from the bone marrow) to treat heart disease. Results have been conflicting; some claim significant improvements in heart function, whilst others report none at all. A group at Imperial College London investigated the possible reasons for this inconsistency and found strange, unexplained discrepancies within reports of many of the clinical trials. They have identified a link between claimed success rates and discrepancies, casting doubts over the validity of this treatment.

- 133 reports of 49 clinical trials were investigated
- 600+ discrepancies were found
- Discrepancies ranged from minor to serious mistakes and misrepresentation of data
- Reports with the most discrepancies claimed most benefit to patients, while those without discrepancies showed no improvement in patients’ conditions 

New centre licenced to manufacture stem cells for human use opens in Galway

The Centre for Cell Manufacturing Ireland (CCMI) is set to launch today at the Regenerative Medicine Institute (REMEDI), National University of Ireland, Galway. It is the first facility in Ireland to receive a licence from the Irish Medicines Board to manufacture expanded stem cells for human use, and one of only five of its kind in Europe.

Stem Cells: From Bench to Bedside, King’s College London

The scale of the medical challenges that an ageing population poses for healthcare in the future will require radical solutions; harnessing the potential of stem cells represents a promising strategy. On 12 November members of the public gathered at King’s College London to discuss issues surrounding stem cell research and how their clinical translation may be realised. 

Unproven stem cell therapy goes to trial

A controversial and unproven stem cell procedure is to be evaluated in a controlled clinical trial, following a vote in the Italian Senate last week.

The Italian Parliament’s Chamber of Deputies had last Monday voted to amend an earlier controversial decree by Italian Senate, which allowed the unproven stem cell method developed by the Stamina Foundation to be used for severely or terminally ill new patients for 18 months.

Spotlight on clinical research for International Clinical Trials Day

Earlier this month our partner ECRIN celebrated International Clinical Trials Day with an event in Warsaw.

What to expect from the new Clinical Trials Directive

A specialist discussion event regarding the revision of the EU Clinical Trials Directive (CTD) was held at the European Parliament Information Office in London on the 22nd of February 2013.  This event was initiated by EuroStemCell and OptiStem in collaboration with the European Parliament Office in London and featured OptiStem Principal Investigator, Prof Michele De Luca as a panellist. Read on for a description of the event from Georgina Massouraki and a storify summary of lots of interesting event tweets, put together by Corin Campbell.

Syndicate content